SCOPUS 정보 검색 플랫폼

Journal of Neurology

Volumn 260, Issue 12, 2013, Pages 2981-2985

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort

(3) Braune, Stefan a,b Lang, M a Bergmann, A a

a NeuroTrans Concept ^* (Germany)

b Neurozentrum Prien (Germany)

Author keywords

Efficacy; Fingolimod; Natalizumab; RRMS

Indexed keywords

FINGOLIMOD; NATALIZUMAB;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DISEASE DURATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG USE; EXPANDED DISABILITY STATUS SCALE; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; OUTPATIENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPENSITY SCORE; RECURRENCE RISK; RELAPSE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GERMANY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTPATIENTS; PROPYLENE GLYCOLS; RECURRENCE; SPHINGOSINE;

EID: 84890788103 PISSN: 03405354 EISSN: 14321459 Source Type: Journal
DOI: 10.1007/s00415-013-7082-0 Document Type: Article

Times cited : (38)

References (6)

1
- 76149093586
- A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
- 20089952 10.1056/NEJMoa0909494 1:CAS:528:DC%2BC3cXhvVWltr4%3D
- Kappos L, Radue EW, O'Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387-401
- (2010) N Engl J Med , vol.362 , Issue.5 , pp. 387-401
- Kappos, L.¹ Radue, E.W.² O'Connor, P.³

2
- 76149140914
- Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
- 20089954 10.1056/NEJMoa0907839 1:CAS:528:DC%2BC3cXhvVWrsbk%3D
- Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402-415
- (2010) N Engl J Med , vol.362 , Issue.5 , pp. 402-415
- Cohen, J.A.¹ Barkhof, F.² Comi, G.³

3
- 33644584352
- A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
- 16510744 10.1056/NEJMoa044397 1:CAS:528:DC%2BD28XitVertL4%3D
- Polman CH, O'Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899-910
- (2006) N Engl J Med , vol.354 , Issue.9 , pp. 899-910
- Polman, C.H.¹ O'Connor, P.W.² Havrdova, E.³

4
- 33644608613
- Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
- 16510745 10.1056/NEJMoa044396 1:CAS:528:DC%2BD28XitVertLw%3D
- Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354(9):911-923
- (2006) N Engl J Med , vol.354 , Issue.9 , pp. 911-923
- Rudick, R.A.¹ Stuart, W.H.² Calabresi, P.A.³

5
- 77951622706
- The central role of the propensity score in observational studies for causal effects
- 10.1093/biomet/70.1.41
- Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70(1):41-55
- (1983) Biometrika , vol.70 , Issue.1 , pp. 41-55
- Rosenbaum, P.R.¹ Rubin, D.B.²

6
- 38849111846
- Stratification for the propensity score compared with linear regression techniques to assess the effect of treatment or exposure
- 18058851 10.1002/sim.3133
- Senn S, Graf E, Caputo A (2007) Stratification for the propensity score compared with linear regression techniques to assess the effect of treatment or exposure. Stat Med 26(30):5529-5544
- (2007) Stat Med , vol.26 , Issue.30 , pp. 5529-5544
- Senn, S.¹ Graf, E.² Caputo, A.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.